加拿大关于管理KRAS G12C突变NSCLC的共识建议
Parneet K Cheema1,2, Shantanu O Banerji3, Normand Blais4
1Division of Medical Oncology, William Osler Health System, University of Toronto, Brampton, ON L6R 3J7, Canada.
克拉斯G12C突变驱动非小细胞肺癌. 建议索托拉西布用于在标准护理下进展的高级NSCLC患者,建议对肝脏进行监测.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 激活KRAS G12C突变在非小细胞肺癌 (NSCLC) 中很常见.
- 新的KRAS G12C抑制剂正在出现,需要临床指导.
- 索托拉西布是一种KRAS G12C抑制剂,已在加拿大获得批准.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Ras Gene
Ras is a...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers
